0001209191-20-020509.txt : 20200320
0001209191-20-020509.hdr.sgml : 20200320
20200320175252
ACCESSION NUMBER: 0001209191-20-020509
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200319
FILED AS OF DATE: 20200320
DATE AS OF CHANGE: 20200320
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Haddadin Yezan Munther
CENTRAL INDEX KEY: 0001718004
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37759
FILM NUMBER: 20733084
MAIL ADDRESS:
STREET 1: ZAHRAN STREET, 7TH CIRCLE ZAHRAN PLAZA
STREET 2: 4TH FLOOR, PO BOX 142904
CITY: AMMAN
STATE: M2
ZIP: 11844
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Outlook Therapeutics, Inc.
CENTRAL INDEX KEY: 0001649989
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 383982704
STATE OF INCORPORATION: DE
FISCAL YEAR END: 0930
BUSINESS ADDRESS:
STREET 1: 7 CLARKE DRIVE
CITY: CRANBURY
STATE: NJ
ZIP: 08512
BUSINESS PHONE: 6096193990
MAIL ADDRESS:
STREET 1: 7 CLARKE DRIVE
CITY: CRANBURY
STATE: NJ
ZIP: 08512
FORMER COMPANY:
FORMER CONFORMED NAME: Oncobiologics, Inc.
DATE OF NAME CHANGE: 20150804
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-03-19
0
0001649989
Outlook Therapeutics, Inc.
OTLK
0001718004
Haddadin Yezan Munther
C/O OUTLOOK THERAPEUTICS, INC.
7 CLARKE DRIVE
CRANBURY
NJ
08512
1
0
0
0
Stock Option (Right to Buy)
0.54
2020-03-19
4
A
0
15000
0.00
A
2030-03-19
Common Stock
15000
15000
D
The options were granted under the Issuer's 2015 Equity Incentive Plan (the "2015 Plan") and shall vest in full on March 19, 2021, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2015 Plan, subject to the Reporting Person providing continuous service to the Issuer through such event.
/s/ Lawrence Kenyon, Attorney-in-Fact
2020-03-20